Pig model of Huntington's offers advantages for testing treatments

March 29, 2018

Using genetic engineering technology, a team of scientists has established a pig model of Huntington's disease (HD), an inherited neurodegenerative disease. The researchers anticipate that the pigs could be a practical way to test treatments for HD, which is caused by a gene encoding a toxic protein that causes brain cells to die.

The research is scheduled for publication in Cell on March 29th.

Although genetically modified mice have been used widely to model neurodegenerative diseases, they lack the typical neurodegeneration or overt neuronal loss seen in human brains, says corresponding author Xiao-Jiang Li, MD, PhD, distinguished professor of human genetics at Emory University School of Medicine.

The pig HD model is an example that suggests large animal models could better model other neurodegenerative diseases, such as Alzheimer's, Parkinson's and ALS (amyotrophic lateral sclerosis), he says. A HD pig could be an opportunity to test if CRISPR-Cas9 gene editing can work in larger animals before clinical applications in humans.

In comparison with mice, delivery of treatments to affected nervous system tissues can be better tested in pigs, because their size is closer to that of humans. The pig model of HD also more closely matches the symptoms of the human disease. Compared with non-human primate models, the pigs offer advantages of faster breeding and larger litter sizes, the researchers say.

The pig model of HD was established by researchers at Emory University School of Medicine, together with colleagues at Jinan University and Chinese Academy of Sciences in Guangzhou.

"We think the pig model will fill an important gap," says co-senior author Shihua Li, M.D, professor of human genetics at Emory University School of Medicine. "In pigs, the pattern of neurodegeneration is almost the same as in humans, and there have been several treatments tested in mouse models that didn't translate to human."

Shihua and Xiao-Jiang Li jointly run a lab at Emory, which collaborated with Liangxue Lai, PhD, associate director of the South China Institute of Stem Cells and Regeneration Medicine, Chinese Academy of Sciences. The lead author of the paper is Sen Yan at Jinan University's Guangdong-Hongkong-Macau Institute of CNS Regeneration. Yan was trained in the Li Lab as a visiting PhD student at Emory. The pigs are housed in Guangzhou.

Symptoms displayed by the genetically altered pigs include movement problems. They show respiratory difficulties, which resemble those experienced by humans with HD and are not seen in mouse models of HD. In addition, the pigs show degeneration of the striatum, the region of the brain most affected by HD in humans, more than other regions of the brain.

Huntington's disease is caused by a gene encoding a toxic protein (mutant huntingtin or mHTT). mHTT contains abnormally long repeats of a single amino acid, glutamine. Symptoms commonly appear in mid-life and include uncontrolled movements, mood swings and cognitive decline.

Researchers used the CRISPR/Cas9 gene editing technique to introduce a segment of a human gene causing Huntington's, with a very long glutamine repeat region, into pig fibroblast cells. Then somatic cell nuclear transfer generated pig embryos carrying this genetic alteration. The alteration is referred to a "knock in" because the changed gene is in its natural context.

Last year, the Li lab published a paper in Journal of Clinical Investigation showing that CRISPR-Cas9 gene editing, delivered by viral vector, can reverse signs of HD in a mouse model. Working with Liangxue Lai, the Li lab has generated transgenic -- not "knock-in" -- pigs that are models for HD. The Li lab also collaborated with Anthony Chan, DVM, PhD at Yerkes National Primate Research Center to generate a transgenic HD monkey model.
-end-
The research was supported by the U.S. National Institute of Neurological Disorders and Stroke (NS101701, NS095279, NS095181), National Key Research and Development Program of China (Stem Cell and Translational Research), the National Natural Science Foundation of China, and Guangdong Province.

Emory Health Sciences

Related Neurodegenerative Diseases Articles from Brightsurf:

Bringing drugs to the brain with nanoparticles to treat neurodegenerative diseases
Researchers from the Institut national de la recherche scientifique (INRS) have shown that nanoparticles could be used to deliver drugs to the brain to treat neurodegenerative diseases.

First 'pathoconnectome' could point toward new treatments for neurodegenerative diseases
Scientists from the John A. Moran Eye Center at the University of Utah have achieved another first in the field of connectomics, which studies the synaptic connections between neurons.

Unlocking the mystery of tau for treatment of neurodegenerative diseases
A team of researchers from various collaborating universities and hospitals in Japan has uncovered crucial molecular details regarding the activity of the ''tau'' protein, promising to revolutionize the therapy of tau-induced neurodegenerative diseases.

Investigational drug stops toxic proteins tied to neurodegenerative diseases
An investigational drug that targets an instigator of the TDP-43 protein, a well-known hallmark of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), may reduce the protein's buildup and neurological decline associated with these disorders, suggests a pre-clinical study from researchers at Penn Medicine and Mayo Clinic.

Inhibition of sphingolipid metabolism and neurodegenerative diseases
Disrupting the production of a class of lipids known as sphingolipids in neurons improved symptoms of neurodegeneration and increased survival in a mouse model.

How understanding the dynamics of yeast prions can shed light on neurodegenerative diseases
How understanding the dynamics of yeast prions can shed light on neurodegenerative diseases

New family of molecules to join altered receptors in neurodegenerative diseases
An article published in the Journal of Medicinal Chemistry shows a new family of molecules with high affinity to join imidazoline receptors, which are altered in the brain of those patients with neurodegenerative diseases such as Alzheimer's, Parkinson's and Huntington's.

Examining diagnoses of stress-related disorders, risk of neurodegenerative diseases
Researchers investigated how stress-related disorders (such as posttraumatic stress disorder, adjustment disorder and stress reactions) were associated with risk for neurodegenerative diseases, including Alzheimer and Parkinson disease and amyotrophic lateral sclerosis (ALS), using data from national health registers in Sweden.

Toxic protein, linked to Alzheimer's and neurodegenerative diseases, exposed in new detail
The protein tau has long been implicated in Alzheimer's and a host of other debilitating brain diseases.

Study uncovers unexpected connection between gliomas, neurodegenerative diseases
New basic science and clinical research identifies TAU, the same protein studied in the development of Alzheimer's, as a biomarker for glioma development.

Read More: Neurodegenerative Diseases News and Neurodegenerative Diseases Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.